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Preeclampsia is a pregnancy-specific disorder affecting ca 3% of all pregnant women.
Preeclampsia is the source of severe pregnancy complications. Later life consequences
for mother and infant include increased risk of cardiovascular disease. Preeclampsia is
caused by the dysfunction of the endothelium with subsequent activation of complement
and coagulation systems. HELLP syndrome is considered to be an extreme complication
of preeclampsia but it can also present independently. Diagnostic symptoms in HELLP
syndrome are Hemolysis, Elevated Liver enzymes, and Low Platelets. Similar phenotype
is present in thrombotic microangiopathies (TMAs) and HELLP syndrome is considered
part of the TMA spectrum. Here, we present a case of severe preeclampsia and HELLP
syndrome, which exacerbated rapidly and eventually led to need of intensive care, plasma
exchange, and hemodialysis. The patient showed signs of hemolysis, disturbance
in the coagulation, and organ damage in liver and kidneys. After comprehensive
laboratory testing and supportive care, the symptoms did not subside and treatment
with complement C5 inhibitor eculizumab was started. Thereafter, the patient started
to recover. The patient had pregnancy-induced aHUS. Earlier initiation of eculizumab
treatment may potentially shorten and mitigate the disease and hypothetically decrease
future health risks of preeclamptic women.
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INTRODUCTION
Preeclampsia is a pregnancy-specific disease affecting 3–5% of all pregnancies (1, 2). It manifests
with newly onset hypertension after 20 weeks of gestation and proteinuria. The placenta is central
in the pathogenesis of the disease by connecting the mother to the fetus (3). The maternal-
fetal interface is the zone where genetically different tissue of fetal origin meets with maternal
circulation, endothelium, and immune system. Often called the disease of theories, one generally
accepted insight is that preeclampsia affects the maternal endothelium causing disturbance in the
function of endothelium, which leads to hypertension and proteinuria (2). In its severe form,
preeclampsia may lead to fetal growth retardation, prematurity, and for the mother it might
cause organ failure in kidneys and liver as well as eclampsia. Furthermore, preeclampsia may
have long-term adverse cardiovascular consequences for the mother and the newborn (4). The
development of the placenta is considered inadequate specifically in the process of maternal spiral
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artery transformation, where the trophoblast cells invade the
maternal side into decidua and transform the arteries into low
resistance conduits, also replacing the maternal endothelium
(5–7). Typically, this remodeling of the uterine arteries is
absent or incomplete especially in severe form of preeclampsia.
High resistance in the constricted uterine arteries causes
turbulent blood flow in to the intervillous space of the placenta
causing oxidative stress and mechanical damage to the placental
villous trees. Resulting damage increases the placental shedding
of microparticles and inflammatory mediators resulting in
generalized endothelial activation and dysfunction (8, 9). These
sequential events in the maternal-fetal interface lead to maternal
hypertension and other symptoms as described above.
HELLP syndrome was first characterized in 1982 by
Weinstein as a separate syndrome, often representing together
with preeclampsia but seen also alone (10, 11). HELLP
syndrome is characterized by hemolysis, elevated liver enzymes,
and low platelets. It often requires intensive care level
observation and symptomatic therapy. The pathogenesis of the
syndrome is still in the shadows. HELLP syndrome shares
common features with thrombotic microangiopathies (TMAs)
such as thrombotic thrombocytopenic purpura (TTP) and
hemolytic uremic syndrome (HUS). TMAs present in diverse
group of diseases with common features of microangiopathic
hemolysis, thrombocytopenia, and organ damage resulting from
microthrombi. In TTP, a genetic defect of, or as in vast
majority of cases, acquired autoantibodies against a disintegrin
and metalloproteinase with thrombospondin type 1 motif 13
(ADAMTS13), the enzyme that cleaves activated von Willebrand
factor (vWF), cause formation of unusually large activated vWF
multimers on endothelial cells leading to platelet thrombi in
small vessels and hemolysis. Typical HUS is caused by Shiga-
toxin producing bacterial infection (especially Escherichia coli)
whereas atypical HUS (aHUS) refers to the type of TMA, in
which genetic deficiencies in the regulators of the alternative
pathway of complement system underlie, which, in the presence
of a trigger may cause the clinical disease (12, 13). The FDA
approved treatment for aHUS is the infusion of complement
C5 antagonist eculizumab, which prevents the formation of
the membrane attack complex (MAC) (Figure 1). Clinically
HELLP shares the same symptoms as classical TMAs: hemolysis,
thrombocytopenia, and organ disorder seen in liver. Depending
on the TMA classification used, HELLP syndrome is usually
categorized as part of secondary or acquired TMAs (Table 1).
In this case study, we report a patient with a complicated
pregnancy-induced TMA and the successful course of treatment.
CASE PRESENTATION
Twenty-nine year old primigravida was referred at gestational
age 34+2 to the Helsinki University hospital outpatient clinic
with upper stomach pain. Initially, her blood pressure was
modestly elevated (133/91 mmHg) and urinary dipstick positive
for protein. The initially reported upper stomach pain was
gradually improving. In the ultrasound scan the fetus had normal
biophysical profile (BPP), the weight estimation was at the −2
SD growth curve. Cardiotocography (CTG) was normal. Blood
hemoglobin (Hb) was 115 g/L, platelets 158 E9/L (normal range
150–360 E9/L), alanine aminotransferase (ALT) was normal (23
U/L). The urinary dipstick was positive for protein (+2) and
calculated proteinuria was 1.6 g/24 h. A decision was made to
initiate cortisone treatment to facilitate the lung maturation of
the baby. The patient was discharged with a plan to return the
next day for control check-up and second dose of cortisone.
As scheduled, she came for control at gestational week 34+4.
Blood pressure was 147/87 mmHg, ALT 23, platelets 177, CTG
and the BPP of the fetus in the ultrasound scan was normal.
She was discharged and another check-up was scheduled. In the
afternoon of the same day, the upper stomach pain returned
and steadily worsened toward the evening. She returned to
the hospital at 2.20 a.m. She was experiencing tight upper
stomach pain, restlessness, and she had vomited two times and
was feeling tremor. The blood pressure was clearly elevated
at 170/94mmHg, urine protein dipstick was strongly positive,
ALT was elevated at 159, Hb 122, and platelets 172. She was
admitted to the prenatal ward. At 4 a.m. she was experiencing
headache. Antihypertensive medication was started (Labetalol
100mg thrice). Urine protein excretion peaked in the night being
13 g/24 h. Subsequently, she started vomiting, had upper stomach
pain, headache, and the CTG monitoring showed decelerations.
The patient was transferred at 7.11 a.m. to the delivery ward and
as the cervix was three centimeters dilatated, the fetal membranes
were artificially broken for the induction of labor. At the same
time the laboratory tests were completed with Hb 122, platelets
172. Lactate dehydrogenase (LD), however, was clearly elevated
at 1231U/L at this time. In the CTG, the decelerations continued
and as bradycardia continued an emergency caesarean section
was performed. Male infant (1960 g,−2 SD) was born at 7.25 a.m.
with umbilical artery pH value of 7.05, BE −6.80, Apgar 1/6/8.
Blood loss in the operation was 400ml.
At 9 a.m. after the caesarean section the mother’s platelets
were low at 49, with Hb of 102. By the afternoon the ALT
had risen to 1800, LD 3570, serum creatinine level was 153
(µmol/L), while platelets decreased to 33. There was disturbance
in the coagulation indicated by low level of fibrinogen (1.1 g/L,
reference values 2–4 g/L) and high level of D-dimer of fibrin (30.2
mg/L, <0.5 mg/L). There was some bleeding from the caesarean
section wound, in which additional sutures were placed. At this
time, eight units of platelets were administered. Potassium level
rose from 4.7 to 5.6 (mmol/L). Hemolysis was clearly observed.
Coombs test was negative. Urine excretion was only 10 ml/h.
The laboratory test showed clearly a severe disease with signs
of damage to both the kidneys and the liver. In addition, there
was disturbance in the coagulation system presenting significant
coagulation and marked fibrinolysis simultaneously. Magnesium
sulfate infusion was started because of hyperreflexia, which is
considered a predictive sign of convulsions, a severe complication
of preeclampsia. Intravenous dexamethasone 10mg was started,
and the patient was transferred into intensive care unit (ICU).
Further, laboratory tests were issued for differential diagnostic
purposes of other medical emergencies (Table 2). The activity of
ADAMTS13 was normal 62% (40–130%), which excludes TTP.
Serum complement C3 (0.52 g/L, 0.71–1.41 g/L) and C4 (0.07
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FIGURE 1 | Eculizumab inhibits terminal pathway of complement activation. Complement activation may be initiated via three pathways of activation, that all lead to
the formation of C5 convertases that have the capacity to activate the terminal pathway leading to formation of the MAC on the target surface. This schematic
(Continued)
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FIGURE 1 | illustration of the complement system shows its most relevant activators (in black font) and inhibitors (in red). The activators may be membrane bound
(oval) or soluble (triangle). The alternative pathway activates spontaneously on all surfaces that do not allow for inhibition by the soluble regulator factor H (FH). FH acts
as the cofactor for inactivation of C3b to iC3b by factor I (FI). Thrombomodulin (TM) enhances FH cofactor activity. Cleaved factor B (FB) together with the activator
C3b forms the alternative pathway convertase, which has the capacity to cleave C3 into C3b creating an amplification loop of alternative pathway activation. Classical
pathway of complement activation may be initiated by for example binding of immune complexes to C1q, while the lectin pathway is activated by mannoses binding
lectin (MBL) or ficolins binding to for example patterns of carbohydrates on microbes. Lectin pathway activation results in mannose-associated serine proteases 1 and
2 (MASP-1 and MASP-2, not pictured) cleaving complement components C4 and C2 to form the classical pathway convertase C4bC2b. C1 inhibitor (C1inh) and
C4bp are the soluble regulators of the classical pathway, while membrane cofactor protein (MCP) and complement receptor 1 (CR1) are membrane bound regulators
of early complement pathways. The formation of C5 convertases initiates the terminal pathway of complement activation and cleavage of C5 in the absence of surface
bound regulators decay accelerating factor (DAF) and MCP. Assembly of MAC is regulated by the surface bound regulator CD59 (protectin). Cleavage of C3 in the
early pathways and C5 in terminal pathway releases anaphylatoxins C3a and C5a and results in inflammation. Eculizumab is a humanized recombinant antibody
against the complement protein C5, which inhibits cleavage of C5 by the C5 convertases thereby regulating the prothrombotic and proinflammatory effects of
complement activation. The patient described in this case report was tested for genetic mutations in genes coding for Factor H (CFH), FHR5, and MCP, CFI, CFB,
THBD, and ADAMTS13 (ADAMTS13), a regulator of the vWF pathway of coagulation cascade (not shown). The results of the genetic testing were negative.
TABLE 1 | HELLP and aHUS diagnostic criteria.
HELLP aHUS
Hemolysis Plasma
haptoglobin below
limit for normal,
plasma lactate
dehydrogenase
> 600 U/L
Non-immunological (Coombs test
negative) hemolysis with red blood cell
fragmentation > 1–2% in peripheral blood
smear, plasma haptoglobin below limit for
normal, and increased plasma lactate
dehydrogenase
Organ
dysfunction
Elevated liver
enzymes: alanine
aminotransferase
> 70U/L
Positive markers of injury (of any organ,
but typically acute kidney injury with serum
creatinine over 200 µmol/L)
Low platelets <100 E9/L Thrombocytopenia (platelet count below
150 E9/L or decrease over 25% from
baseline)
g/L, 0.12–0.34 g/L) levels were low. Level of soluble terminal
complex of the complement (C5b-9, 971 ng/mL, <366 ng/mL)
was elevated on the first postpartum day. Antiphospholipid
antibodies were not detected, the infection serology concerning
Hepatitis B and C, and HIV was negative. From stool sample, the
pathogens causing typical HUS tested negative.
The patient was treated with plasma exchange treatment
on first and second postpartum day and was hemodialyzed
altogether three times over the course of her treatment (days 2,
4, and 6 postpartum).
On third postpartum day the patient was stable and
transferred back to Women’s Hospital recovery room
were observation and symptomatic therapy was continued.
Hypertension was treated with Amlodipine 10mg twice a
day and Labetalol 200mg three times a day. On the fourth
postpartum day, platelets continued decreasing and the patient
was diagnosed with aHUS. Often the differential diagnosis with
HELLP syndrome and aHUS lies in spontaneous recovery of
HELLP patients usually on third postpartum day. Treatment
with eculizumab was started (900mg IV). Patient received
a pneumococcal vaccination and prophylactic antibiotic
(penicillin) was started. The patient received all together four
weekly doses of eculizumab (900mg) and she started to recover
rapidly. She did not require further hemodialysis after her
third hemodialysis on the sixth postpartum day (Figure 2).
Kidney function corrected gradually, platelet count elevated, and
hemolysis resolved. Four weeks postpartum the plasma levels of
C3 and C4 were normalized.
In genetic testing, no known gene polymorphisms were
identified. She was tested for mutations in complement
regulators Factor H (CFH), Factor H related protein 5
(FHR5), and membrane co-factor protein (MCP), complement
alternative pathway inactivator factor I (CFI), alternative
pathway activator factor B (CFB), and the following components
of the coagulation cascade: ADAMTS13, thrombomodulin
(THBD), and an intracellular enzyme, diacylglycerol kinase E
(DGKE), whose mutations are a known causes of aHUS (14).
Furthermore, antibodies against factor H were not detected
either. No C4 deficiency was detected.
As a summary, our patient had severe preeclampsia and
fulfilled diagnostic criteria for HELLP syndrome. Although
genetic testing for aHUS remained negative, the clinical course of
the disease (especially, severe acute kidney injury) and response
to treatment (especially, eculizumab) suggested that our patient
had pregnancy-induced aHUS.
DISCUSSION
The primigravida described above was diagnosed with severe
preeclampsia, HELLP syndrome, and pregnancy-induced aHUS.
No known gene mutations, which could predispose to aHUS
were discovered. Differential diagnosis between types of TMA,
TTP, HUS/aHUS, and secondary TMAs like HELLP syndrome
is important. Especially TTP must be identified early on, as
the disease is treated with rapid daily plasma exchange until
remission (15).
At present, laboratory analysis methods for testing genetic
mutations potentially causing aHUS are able to show mutations
in only up to 40–60% of aHUS cases, leaving the possibility of
false negative cases. Therefore, a negative test result for mutations
does not rule out a true aHUS (16). Rarely aHUS has been
induced after pregnancy and parturition. In these cases, during
the following three years∼50% developed chronic kidney disease
(CKD), some even end-stage kidney disease (ESKD). When
genetic mutations were observed, up to 85% may develop CKD
or ESKD (17).
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TABLE 2 | Timeline of the disease diagnostics and treatment.
Days Diagnostics Treatment Aim
Ceasarean section Basic blood count,
C-reactive protein, blood chemical values,
hemolysis markers, coagulation factors and descriptive,
antiphospholipid antibodies, Coombs test, plasma
ADAMTS13 activity, and antinuclear antibodies
Transfer to ICU To exclude TTP, antiphospholipid
syndrome, SLE, and
autoimmune hemolytic anemia
Postpartum day 1 Plasma C3 and C4 levels, Complement terminal
complex-level, C4A and C4B genetic testing
Plasma exchange
Postpartum day 2 Hepatitis B and C, HIV,
and aHUS genetic tests (Complement system)
Plasma exchange,
Hemodialysis
To exclude viral hepatitis as a
cause of liver damage
Postpartum day 3 Stool sample testing the pathogens causing typical HUS Transfer back to Women’s Hospital recovery
room were observation and symptomatic
therapy continued
To exclude typical HUS
Postpartum day 4 Basic laboratory tests concerning hemolysis, liver and
kidney function, platelets, and coagulation
Hemodialysis,
Transfer to the department of Nephrology,
first dose of Eculizumab
Diagnosis of aHUS was placed
Postpartum day 5 Basic laboratory tests concerning hemolysis, liver and
kidney function, platelets, and coagulation
Postpartum day 6 Basic laboratory tests concerning hemolysis, liver and
kidney function, platelets, and coagulation
Hemodialysis
FIGURE 2 | Selected laboratory values observed during the early stages of the disease and the timing of plasma exchange, hemodialysis and administration of
eculizumab. In panel (A) is represented the development of blood hemoglobin measurements, in panel (B) the serum creatinine level, in panel (C) the number of
platelets, and in panel (D) D-dimer of fibrin values across the 17 day follow-up period.
It is generally accepted that in hypertensive disorders
of pregnancy, placental inflammation results in endothelial
dysfunction. If the integrity of the endothelium is disturbed
this results in activation of complement and coagulation (18).
Disrupted maternal endothelium has also been hypothesized to
contribute to the later life maternal morbidity associated with
severe preeclampsia and other hypertensive pregnancy disorders
(2, 19). Damaged endothelium has been shown to function
abnormally even years after the initial diagnostic symptoms
subside (20–23).
In up to 46% of HELLP patients, gene mutations have been
described in the regulators of the alternative pathway of the
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complement system (24, 25). In the early stages of pregnancy,
when the placenta is developing, activation of complement
system is seen in elevated levels of Bb in the serum in
patients who later developed preeclampsia (26). Activation of the
complement system has been observed in severe preeclampsia
and HELLP syndrome, and elevated levels of terminal complex
(C5b-9) have been detected in urine of patients with severe
preeclampsia. In patients with HELLP syndrome, increased
activation of complement system was shown by functional test
and, furthermore, by deficiencies of expression in CD55 and
CD59, leading to decreased regulation and exacerbated activation
of the complement system (27–29).
There are many similarities shared between HELLP syndrome
and aHUS. In both conditions, endothelium disturbance is
clearly involved followed by complement and coagulation
activation. In severe preeclampsia and HELLP syndrome,
eculizumab given at the early signs of severe disease and TMA
would be beneficial for the protection of the kidneys and
maternal endothelium (30). Preserving endothelial integrity may
potentially protect the patient from long term health risks such as
cardiovascular diseases. Typically, in pregnancy-related TMAs,
clinical findings of hemolysis, and thrombocytopenia resolve in
∼3 days. If disease activity lasts longer, differential diagnostics
are to be continued and only then is alternative treatment
(e.g., eculizumab) considered. Introducing eculizumab treatment
earlier would benefit women by preventing kidney damage
and minimizing the turbulence in endothelium and systemic
inflammation. Eculizumab, given early enough and as few as one
or two doses, could possibly be sufficient to stop the turbulence
and be enough to stop the cascade of events (31). On one hand,
eculizumab is a very expensive medication, but on the other, the
cost of intensive care treatment, plasma exchange, hemodialysis,
possible kidney transplantation, not to mention the emotional
consequences for the mothers and families remain inestimable.
As a conclusion, our patient was severely ill, experiencing
hemolysis, disturbance in the coagulation, liver damage, and
kidney failure needing admission to ICU and hemodialysis. It is
possible that eculizumab, if initiated earlier, at the first signs of
HELLP syndrome, might have been beneficial during the later
course of the disease, potentially mitigating kidney injury, and
thus preventing need for hemodialysis and later CKD. Therefore,
in this era of modern immunological medicine, could we do
more for the mothers and families than just wait and hope
for the best?
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